Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Immunohistochemical study on the expression of matrix metalloproteinase 2 and high-risk human papilloma virus in the malignant progression of papillomas

  • Lee, Ho-Jin (Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyungpook National University) ;
  • Kim, Jin-Wook (Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyungpook National University)
  • Received : 2013.08.16
  • Accepted : 2013.09.23
  • Published : 2013.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Papilloma frequently develops as a benign tumor of the head and neck area, but its potential for malignant transformation has yet to be studied. This study aims to provide basic information for papillomas using the immunohistochemical staining of matrix metalloproteinase 2 (MMP-2) and human papilloma virus (HPV) 16 and 18. Materials and Methods: To evaluate the malignant transformation of papillomas, the selected tissue samples were serially diagnosed with pre-cancerous papilloma (with epithelial dysplasia, pseudo-epitheliomatous hyperplasia) or malignant lesion (squamous cell carcinoma, SCC) after the first diagnosis (squamous papilloma, inverted papilloma). The selected tissues were stained with an antibody to MMP-2 and HPV 16-E7, HPV 18-L1. A statistical analysis was performed according to each transformation step. Results: The epithelial layer of papilloma and pre-cancerous papilloma lesions had a similar MMP-2 expression, but that of the malignant lesion had a significantly increased MMP-2 expression. HPV 16 and 18 infection rates were 28.6%, 33.3% and 63.6% in papillomas, pre-cancerous papilloma lesions, and SCC. Conclusions: A relatively high MMP-2 expression and HPV 16 or 18 infection of papillomas may be associated with early events in the multistep processes of malignant transformation of papillomas.

Keywords

References

  1. Sapp JP, Eversole LR, Wysocki GP. Contemporary oral and maxillofacial pathology. St. Louis: Mosby; 1997.
  2. Underbrink MP, Hoskins SL, Pou AM, Albrecht T. Viral interaction: a possible contributing factor in head and neck cancer progression. Acta Otolaryngol 2008;128:1361-9. https://doi.org/10.1080/00016480801965001
  3. Atula S, Auvinen E, Grenman R, Syrjanen S. Human papillomavirus and Epstein-Barr virus in epithelial carcinomas of the head and neck region. Anticancer Res 1997;17:4427-33.
  4. Umudum H, Rezanko T, Dag F, Dogruluk T. Human papillomavirus genome detection by in situ hybridization in fine-needle aspirates of metastatic lesions from head and neck squamous cell carcinomas. Cancer 2005;105:171-7. https://doi.org/10.1002/cncr.21027
  5. Capone RB, Pai SI, Koch WM, Gillison ML, Danish HN, Westra WH, et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res 2000;6:4171-5.
  6. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20. https://doi.org/10.1093/jnci/92.9.709
  7. Scheckenbach K, Lieven O, Götte K, Bockmühl U, Zotz R, Bier H, et al. p53 codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev 2004;13:1805-9.
  8. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45. https://doi.org/10.3109/07853899909019260
  9. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004;1705:69-89.
  10. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. Modulation of human renal cell carcinoma 786-0 MMP-2 and MMP-9 activity by inhibitors and inducers in vitro. Med Oncol 2006;23:245-50. https://doi.org/10.1385/MO:23:2:245
  11. Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral Oncol 1999;35:227-33. https://doi.org/10.1016/S1368-8375(99)00004-4
  12. Kim MK, Lee EH, Kim J, Lee EW, Cha IH. Immunohistochemical study on expression of MMP-2 and MMP-9 in irritation fibroma, oral leukoplakia and oral squamous cell carcinoma. J Korean Oral Maxillofac Surg 2006;32:352-9.
  13. da Silva Cardeal LB, Brohem CA, Corrêa TC, Winnischofer SM, Nakano F, Boccardo E, et al. Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. Biochem Cell Biol 2006;84:713-9. https://doi.org/10.1139/o06-084
  14. Katori H, Nozawa A, Tsukuda M. Increased expression of matrix metalloproteinase-2 and 9 and human papilloma virus infection are associated with malignant transformation of sinonasal inverted papilloma. J Surg Oncol 2006;93:80-5. https://doi.org/10.1002/jso.20386
  15. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70. https://doi.org/10.1093/jnci/89.17.1260
  16. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-8. https://doi.org/10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C
  17. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993;67:1126-31. https://doi.org/10.1038/bjc.1993.207
  18. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995;64:355-9. https://doi.org/10.1002/ijc.2910640513
  19. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7. https://doi.org/10.1186/bcr65
  20. Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol 1997;183:377-9. https://doi.org/10.1002/(SICI)1096-9896(199712)183:4<377::AID-PATH951>3.0.CO;2-R
  21. Gissmann L, Diehl V, Schultz-Coulon HJ, zur Hausen H. Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol 1982;44:393-400.
  22. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 1995;64:1-378.
  23. Arndt O, Johannes A, Zeise K, Brock J. High-risk HPV types in oral and laryngeal papilloma and leukoplakia. Laryngorhinootologie 1997;76:142-9. https://doi.org/10.1055/s-2007-997403
  24. Miller CS, White DK. Human papillomavirus expression in oral mucosa, premalignant conditions, and squamous cell carcinoma: a retrospective review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:57-68. https://doi.org/10.1016/S1079-2104(96)80378-7
  25. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:622-35. https://doi.org/10.1067/moe.2001.115392

Cited by

  1. Advances in recurrence and malignant transformation of sinonasal inverted papillomas vol.13, pp.6, 2013, https://doi.org/10.3892/ol.2017.6089